OncoSec Medical Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor OncoSec Medical te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

OncoSec to cut workforce by 45% as part of corporate restructuring

Oct 04

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

Jan 28

Dosing underway in OncoSec's Tavo combo trial in skin cancer

Jan 08

OncoSec: Undervalued And Continuing To Make Progress

Nov 18

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

Nov 09

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat OncoSec Medical onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:ONCS.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
1/31/2023	N/A	-29	-25	-25	N/A
10/31/2022	N/A	-32	-29	-28	N/A
7/31/2022	N/A	-34	-32	-32	N/A
4/30/2022	N/A	-38	-34	-34	N/A
1/31/2022	N/A	-41	-42	-41	N/A
10/31/2021	N/A	-42	-43	-42	N/A
7/31/2021	N/A	-45	-43	-42	N/A
4/30/2021	N/A	-42	-44	-43	N/A
1/31/2021	N/A	-43	-38	-38	N/A
10/31/2020	N/A	-46	-35	-35	N/A
7/31/2020	N/A	-42	-33	-33	N/A
4/30/2020	N/A	-41	-32	-32	N/A
1/31/2020	N/A	-38	-31	-31	N/A
10/31/2019	N/A	-32	-30	-30	N/A
7/31/2019	N/A	-30	-29	-29	N/A
4/30/2019	N/A	-35	-27	-27	N/A
1/31/2019	N/A	-38	-25	-25	N/A
10/31/2018	N/A	-41	-25	-25	N/A
7/31/2018	N/A	-39	-23	-23	N/A
4/30/2018	N/A	-33	-22	-22	N/A
1/31/2018	N/A	-27	-20	-20	N/A
10/31/2017	N/A	-22	-18	-18	N/A
7/31/2017	N/A	-21	-17	-17	N/A
4/30/2017	N/A	-22	-17	-17	N/A
1/31/2017	N/A	-24	-18	-17	N/A
10/31/2016	N/A	-25	N/A	-18	N/A
7/31/2016	N/A	-27	N/A	-18	N/A
4/30/2016	N/A	-27	N/A	-19	N/A
1/31/2016	N/A	-27	N/A	-19	N/A
10/31/2015	N/A	-24	N/A	-19	N/A
7/31/2015	N/A	-21	N/A	-18	N/A
4/30/2015	N/A	-18	N/A	-15	N/A
1/31/2015	N/A	-16	N/A	-13	N/A
10/31/2014	N/A	-14	N/A	-10	N/A
7/31/2014	N/A	-12	N/A	-9	N/A
4/30/2014	N/A	-10	N/A	-8	N/A
1/31/2014	N/A	-8	N/A	-7	N/A
10/31/2013	N/A	-7	N/A	-6	N/A
7/31/2013	N/A	-7	N/A	-6	N/A
4/30/2013	N/A	-7	N/A	-6	N/A
1/31/2013	N/A	-6	N/A	-5	N/A
10/31/2012	N/A	-7	N/A	-5	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van ONCS.Q boven de spaarquote ( 2.1% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van ONCS.Q naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van ONCS.Q naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van ONCS.Q naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van ONCS.Q naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ONCS.Q naar verwachting over 3 jaar hoog zal zijn

OncoSec Medical Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$5.00

Price target decreased to US$5.00

Forecast to breakeven in 2024

Price target raised to US$8.13

Recent updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma

Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Announces Workforce Reduction

OncoSec to cut workforce by 45% as part of corporate restructuring

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer

Price target decreased to US$5.00

Less than half of directors are independent

OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022

Price target decreased to US$5.00

OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Less than half of directors are independent

Interim CEO & COO Brian Leuthner has left the company

Forecast to breakeven in 2024

President, CEO & Director Daniel O'Connor has left the company

OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021

Price target raised to US$8.13

OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development

OncoSec Medical Incorporated Announces Management Appointments

New 90-day high: US$7.71

OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

New 90-day high: US$6.81

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Dosing underway in OncoSec's Tavo combo trial in skin cancer

New 90-day high: US$6.65

OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology

OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

OncoSec: Undervalued And Continuing To Make Progress

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

New 90-day high: US$5.11

OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer

OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven